Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) is frequently featured in healthcare and capital markets news as a global medical technology company focused on neurosurgery, tissue reconstruction, and regenerative care. Its news flow, as reflected in recent press releases, spans financial results, regulatory milestones, clinical technology updates, policy developments, and investor conference participation.
Investors following IART news will see regular quarterly earnings announcements, typically accompanied by detailed segment commentary for Codman Specialty Surgical and Tissue Technologies, as well as discussions of organic revenue trends, adjusted profitability metrics, and management’s outlook. These releases are often paired with notices of conference calls and webcasts accessible through the company’s investor relations channels.
Beyond financial reporting, Integra issues news on regulatory and clinical developments. Recent examples include FDA 510(k) clearance for expanded use of the CUSA Clarity Ultrasonic Surgical Aspirator System in cardiac surgery and updates on neurosurgical technologies such as CereLink, Aurora, Mayfield devices, and Durepair Dura Regeneration Matrix. The company also highlights its presence at major clinical meetings, including the Congress of Neurological Surgeons Annual Meeting, where it showcases its neurosurgical portfolio.
Policy and reimbursement developments are another theme in Integra’s news. The company has commented on CMS rules affecting Medicare beneficiary access to skin substitutes, noting the inclusion of its dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes, as well as specific brands like Integra matrices, PriMatrix, Cytal, and AmnioExcel.
In addition, IART news covers leadership and governance updates, such as the appointment of a chief medical officer and participation by senior executives in investor healthcare conferences. For readers and investors, the IART news page offers a centralized view of Integra’s financial performance, product and regulatory milestones, policy environment, and corporate developments.
Integra LifeSciences (Nasdaq: IART) said CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on Integra LifeSciences' investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq: IART) announced that CEO Mojdeh Poul and CFO Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m. ET. A live webcast will be available on the company investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq: IART) welcomed the Centers for Medicare & Medicaid Services CY 2026 Medicare Physician Fee Schedule and OPPS rules that include all Integra skin substitutes. The ruling covers Integra matrices, PriMatrix, Cytal and AmnioExcel across four distinct technology platforms and establishes a uniform reimbursement rate across care settings.
The company said the change positively affects multiple regulatory pathways, including its FDA‑approved PMA Integra Dermal Regeneration Template, and enables expansion of commercial presence beyond hospitals to increase patient access to wound reconstruction products.
Integra LifeSciences (Nasdaq:IART) announced FDA 510(k) clearance for the CUSA® Clarity Ultrasonic Surgical Aspirator System for use in cardiac surgeries on Nov 11, 2025.
The clearance specifically covers debridement of unwanted tissue in cardiac surgeries, including use during valve replacement and repair. The system retains its broader indications for fragmentation, emulsification and aspiration of soft and hard tissue across specialties such as neurosurgery, orthopedic, thoracic, laparoscopic, gynecological, plastic/reconstructive, and liver resection/transplant surgery.
Integra will spotlight CUSA Clarity at the AATS Mitral Valve Conclave in New York City on Dec 11–12, 2025.
Integra LifeSciences (Nasdaq: IART) reported third quarter 2025 results with $402.1M revenue, up 5.6% reported and 5.0% organic year-over-year, and adjusted EPS $0.54 vs $0.41 prior year. Adjusted EBITDA was $78.5M (19.5% margin). GAAP net loss narrowed to $5.4M (−$0.07 per share). Cash flow from operations was $40.9M; total debt $1.8B and leverage 4.3x. Company relaunched PriMatrix and Durepair via dual sourcing, relaunched supply actions, appointed a new CMO, and updated full-year 2025 revenue guidance to $1.62–$1.64B with adjusted EPS $2.19–$2.24.
Integra LifeSciences (Nasdaq: IART) will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. Management will host a conference call the same day at 8:30 a.m. ET.
A live webcast will be available on the company Investors website at investor.integralife.com. Participants may register to receive dial-in details and an individual PIN; joining 10 minutes early is recommended. A webcast replay will be posted on the Investors website after the call.
Integra LifeSciences (Nasdaq: IART) will exhibit at the Congress of Neurological Surgeons Annual Meeting in Los Angeles from October 11–15, 2025. The company will showcase neurosurgical devices including Durepair Dura Regeneration Matrix and Mayfield Ghost Base Unit, Post, plus CereLink ICP Monitoring System, CUSA Clarity Tissue Ablation System, Aurora Surgiscope System, and Certas Plus Programmable Valve. Integra will be at booth #713 to engage neurosurgeons and demonstrate product features aimed at improving surgical visualization and dural repair.
Integra LifeSciences (Nasdaq:IART) has appointed Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings over 20 years of surgical and leadership experience from major MedTech companies, including Siemens Healthineers and Johnson & Johnson.
In his new role, Dr. Turner will lead worldwide medical affairs and clinical development activities, while maintaining his clinical practice. His extensive background includes serving as chief medical officer at Siemens Endovascular Robotics and program director at the Medical University of South Carolina. Dr. Turner has authored over 150 peer-reviewed publications and participated in more than 70 research studies.
Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, announced its executive leadership participation in two upcoming healthcare investor conferences. CEO Mojdeh Poul and CFO Lea Knight will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ET, and the Morgan Stanley Healthcare Conference on September 10, 2025, at 8:30 a.m. ET.
Investors can access live webcasts of both presentations through Integra LifeSciences' investor relations website under the Events & Presentations section.
Integra LifeSciences (NASDAQ: IART) reported mixed Q2 2025 financial results with revenues of $415.6 million, showing a slight decline of 0.6% reported and 1.4% organic year-over-year. The company posted a significant GAAP net loss of $(6.31) per share, primarily due to a $511 million goodwill impairment charge, compared to $(0.16) in the prior year.
The Codman Specialty Surgical segment (~70% of revenues) reached $304.0 million, growing 0.7% reported, while Tissue Technologies (~30%) declined 4.1% to $111.6 million. The company updated its full-year 2025 revenue guidance to $1.655-1.680 billion and maintained adjusted EPS guidance of $2.19-2.29.
Integra is implementing a Compliance Master Plan and has completed all manufacturing site assessments, while launching profitability initiatives to drive efficiency gains over the next 12-18 months.
FAQ
What is the current stock price of Integra Lifesciences Hldgs Cp (IART)?
What is the market cap of Integra Lifesciences Hldgs Cp (IART)?
